In addition, IL-17A response is associated strongly with acute ABPA, and its specific decline in response to ABPA treatment suggests that this atypical Th17 response plays an active role in manifesting and/or exacerbating disease [30]. This evidence concerns the gene IL17A and allergic bronchopulmonary aspergillosis.